

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
6 May 2004 (06.05.2004)

PCT

(10) International Publication Number  
**WO 2004/037242 A1**

(51) International Patent Classification<sup>7</sup>: **A61K 31/192**

(21) International Application Number:  
PCT/EP2003/011689

(22) International Filing Date: 22 October 2003 (22.10.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
02023954.7 25 October 2002 (25.10.2002) EP

(71) Applicant (for all designated States except US): **DOMPE S.P.A.** [IT/IT]; Via Campo di Pile, I-67100 L'Aquila (IT).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **GENTILE, Marco, Maria** [IT/IT]; Via Campo di Pile, I-67100 L'Aquila (IT). **DRAGANI, Maria, Concetta** [IT/IT]; Via Campo di Pile, I-67100 L'Aquila (IT).

(74) Agent: **PIERACCIOLI, Daniele**; Dompé S.p.A., Via San Martino, 12, I-20122 Milano (IT).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

**Declarations under Rule 4.17:**

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) for the following designation US
- of inventorship (Rule 4.17(iv)) for US only

**Published:**

- with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: PAINLESS INJECTABLE COMPOSITIONS CONTAINING SALT OF 2-ARYLPROPIONIC ACIDS

(57) Abstract: Pharmaceutical compositions are described, containing an alkylammonium salt of a 2-arylpropionic acid, which are suitable for parenteral administration and do not generate pain upon injection. The compositions contain preferably ketoprofen, ibuprofen, naproxen or tiaprofenic acid in aqueous solution at pH in the range between 8 and 9. The alkylammonium salt is preferably a L-lysine salt. Compositions at pH=8,5 have shown to cause less pain upon injection than other known compositions.



WO 2004/037242 A1

**No pain injectable compositions containing salts of 2-arylpropionic acids**

The present invention relates to pharmaceutical compositions suitable for parenteral administration, which contain alkylammonium salts of 2-arylpropionic acids and which generate no pain upon injection. In particular, the compositions contain ketoprofen, ibuprofen or naproxen in alkaline aqueous solutions.

**BACKGROUND OF THE INVENTION**

A common limitation in the administration of parenteral products is the onset of pain in the site of injection, that may result from the active drug, the formulation components, or the total formulation. In the development of a parenteral product the attention is mainly focused on the chemical, physical and microbiological stability and on the general safety of the formulation, considering the route of administration, while pain at injection site, that is a negative peculiarity of injectable drug formulations, do not receive much consideration. This is mainly due to the lack in the number and type of models available to study the physiology and mechanisms of pain, the difficulty, variability and cost associated with the use of animal models to evaluate pain and the necessity to use subjective versus objective measures (which often involve extensive experimental set-ups) to evaluate the extent of pain either in animals or humans.

It is possible that a given formulation can cause tissue damage that results in pain at the injection site; in this case toxicity screening methods, like red blood cells hemolysis, or L6 myoblast cell line method, or the rodent *in vivo* muscle model, can give a rational approach to develop and select the optimal formulations with respect to the desired physicochemical properties and tissue tolerability (Brazeau G.A. et al., "Current perspectives on pain upon injection of drug", Journal of Pharm. Sciences, 87, 6, June 1998).

If, in contrast, there is no indication of any type of tissue damage at the site of injection, before testing any injectable formulations in humans, it is useful to have

methods to screen formulations early during development, for their potential to cause pain.

One of these methods is the rat paw-lick model, used as a rapid *in vivo* screening method for parenteral products, but not always results are obtained, which are subsequently confirmed by clinical data.

#### BRIEF DESCRIPTION OF THE INVENTION

During our experiments in animals, we have observed that solutions containing ketoprofen at different pH and composition, when instilled in rat's eye, cause reaction in animals by means of an increased number of winks, if compared with instillation of water for injection alone. Supposing that winks are somehow related to pain upon injection, the rat wink test may be used as an alternative animal model for the evaluation of the extent of pain caused by injectable pharmaceutical compositions.

In humans, a well known clinical method of evaluating the painfulness of injectable solutions uses the VAS (Visual Analogue Scale) value as an index (Scott and Huskinsson, Pain, 2:175-184, 1976). VAS number is an evaluation of the intensity of pain at the injection site immediately after injection and after some lag times in humans; the result is expressed using the 100 mm Visual Analogue Scale.

Clinical studies have thus been performed using two ketoprofen injectable compositions at optimum pH, which had caused less pain in the rat wink test. The evaluation of pain upon injection has been performed in comparison with a classical formulation of ketoprofen in phosphate buffer at pH 6.5 and with the commercial preparation "Artrosilene<sup>®</sup> fiale", ampoules for injection (Dompé farmaceutici S.p.A.) containing ketoprofen lysine salt in an aqueous solution at pH adjusted between 7 and 7.5 with citric acid and sodium hydroxide, and not containing co-solvents, such as benzyl alcohol, which are usually used in injectable formulations to decrease pain upon injection (WO 97/24114).

“Artrosilene® fiale” is known to cause less pain upon injection than the classical formulations of ketoprofen.

We have now found that compositions for parenteral administration containing alkylammonium salts of 2-arylpropionic acids, such as ketoprofen, ibuprofen, naproxen or tiaprofenic acid, in alkaline aqueous solutions do not cause any pain upon injection.

The present invention thus provides a pharmaceutical composition suitable for parenteral administration having anti-inflammatory and analgesic property, characterized in that it contains an alkylammonium salt of a 2-arylpropionic acid selected from ketoprofen, ibuprofen, naproxen or tiaprofenic acid, in racemic or in enantiomeric form, in an aqueous solution at a pH in the range between 8 and 9, said solution being free of preservatives, co-solvents and supporting substances.

Preferred compositions contain ketoprofen as a salt of L-lysine.

More preferred compositions contain ketoprofen L-lysine salt, sodium bicarbonate and sodium hydroxide at pH 8.5.

#### DETAILED DESCRIPTION OF THE INVENTION

Different formulations of ketoprofen L-lysine salt in aqueous solution at different pH have been prepared and tested in the rat wink test as defined above. Suitable formulations have been selected from this assay and compared with classical ketoprofen formulations at pH 6.5 and with the commercial preparation of ketoprofen “Artrosilene® fiale”. Solutions in a range of pH between 8 and 9 have not caused any pain upon injection and have been shown to be much better than Artrosilene® in this respect.

A correlation between the rat wink test and the clinical test based on the VAS value has also been found.

Materials used in the experiments are reported in Table 1:

Table 1

	<i>Supplier</i>
Ketoprofen lysine salt	Dompé
NaOH 1N	Riedel-de Haën
HCl 35%	Carlo Erba
NaHCO <sub>3</sub>	G. Faravelli
NaCl 0,9% solution	Bieffe Medital
Artrosilene <sup>®</sup> fiale	Dompé farmaceutici S.p.A.
Water for injectable preparations	Bieffe Medital

All formulations tested are 8% aqueous solutions of ketoprofen L-lysine salt. Solutions with different pH have been prepared, using a NaOH 1N solution, or a HCl 35% solution to adjust pH. In some preparations NaHCO<sub>3</sub> was also added at the concentration of 4 mg/mL.

Artrosilene<sup>®</sup> and NaCl 0.9% solution were extracted from their original ampoules and bottles and were packaged in dark glass vials provided with polymeric cap and aluminium ring. The specific composition, pH and osmolality of the formulations tested in two different experiments are reported in Tables 2 and 3.

Table 2-First Experiment

<i>Batch</i>	<i>Composition</i>	<i>pH</i>	<i>Osmolality (mOsmol/kg)</i>
PG054/34/SU01	KSL + HCl	7.0	308
PG054/35/SU01	KSL	7.2	267
PG054/36/SU01	KSL + NaOH	8.0	289
PG054/37/SU01	KSL + NaOH	9.0	333
PG054/38/SU01	KSL + NaOH	9.5	403
PG054/53/SU01	KSL + NaOH	8.5	382
PG054/45/SU01	KSL + NaHCO <sub>3</sub>	7.0	359
PG054/46/SU01	KSL + NaHCO <sub>3</sub> + NaOH	7.5	351
PG054/47/SU01	KSL + NaHCO <sub>3</sub> + NaOH	8.0	358
PG054/48/SU01	KSL + NaHCO <sub>3</sub> + NaOH	8.5	382

PG054/49/SU01	KSL + NaHCO <sub>3</sub> + NaOH	9.0	395
PG054/50/SU01	KSL + NaHCO <sub>3</sub> + NaOH	9.5	455

Table 3-Second Experiment

<i>Batch</i>	<i>Composition</i>	<i>pH</i>	<i>Osmolality (mOsmol/kg)</i>
PG054/62/SU01	KSL + NaHCO <sub>3</sub> + HCl	7.0	356
PG054/63/SU01	KSL + HCl	7.0	276
PG054/64/SU01	KSL + NaHCO <sub>3</sub> + NaOH	8.0	362
PG054/65/SU01	KSL + NaOH	8.0	282
PG054/66/SU01	KSL + NaHCO <sub>3</sub> + NaOH	9.0	399
PG054/67/SU01	KSL + NaOH	9.0	336
PG054/70/SU01	KSL + NaOH	7.5	268
PG054/71/SU01	KSL + NaOH	8.5	301
PG054/72/SU01	KSL + NaOH	9.5	405
PG054/75/SU01	KSL + NaHCO <sub>3</sub> + NaOH	7.5	354
PG054/76/SU01	KSL + NaHCO <sub>3</sub> + NaOH	8.5	384
PG054/77/SU01	KSL + NaHCO <sub>3</sub> + NaOH	9.5	463

*Animals*

The animals used in the experiments are described herebelow:

Species:	rat
Strain:	Sprague-Dawley
Supplier:	Charles-River (Calco, L.C, Italy)
Sex:	male
Age:	5-7 weeks
Body weight at arrival:	176-200 g

On arrival the animals were housed five per cage (Makrolon<sup>®</sup> 3G type, Tecniplast Gazzada S.r.l., Buguggiate, VA, Italy) and acclimated for at least 6 days in the animal room.

Poplar and fir chips, heat-processed for resin removal and dust-free, were used for bedding.

Contaminants that might interfere with the purpose of the study, were not expected to be present in the wood.

Animal room temperature was 20°C ± 2 and relative humidity was 55% ± 10.

Room illumination: 12-hour artificial light (7.00 am - 7.00 pm), 12-hour dark (7.00 pm-7.00 am).

The animals were feeded with pellets provided by Laboratorio Dottori Piccioni, Gessate, Milano, Italy. According to the analytical certificates provided by the supplier, the contents of contaminants were within the limits proposed by EPA-TSCA (44 Fed. Reg. 44053-44093 July 26,1979).

Contaminants that might interfere with the purpose of the study were not expected to be present either in the diet or in the water provided to the animals.

Food and water were supplied *ad libitum* during acclimatisation.

The different formulations of ketoprofen were administered in the eye of each animal and the number of winks in each case was determined in a fixed amount of time. In all experiments 25µL of each formulation were instilled in the rat's eye using a Gilson pipette.

#### *Formulation*

ketoprofen L-lysine salt	160 mg
sodium bicarbonate	8 mg
sodium hydroxide	3 mg
water for injection q.s.	2 ml

#### *Preparation method*

160mg of ketoprofen L-lysine salt and 3 mg of sodium hydroxide are added to 1.6ml of water for injection. Sodium bicarbonate (8mg) is than added to the solution, then water for injection is added up to 2ml.

#### **Example 1**

##### Rat wink test

In the first session of each experiment, 25 µL of each formulation were instilled into rats' left eye. In the second session 25 µL of each formulation were instilled in the same rats' right eye.

In each session, rats' winks were counted within 15 seconds from instillation (time was taken by means of a chronometer).

The time elapsed between the two experiments was 8 days.

Results of the first experiment are reported in Tables 4 and 5. Figure 1 outlines the pH-response profile observed in the first experiment.

Results of the second experiment are reported in Tables 6 and 7. Figure 2 outlines the pH-response profile observed in the second experiment.

**Table 4 - First session – First experiment**

<i>Batch</i>	<i>Composition</i>	<i>pH</i>	<i>Osmolality (mOsmol/kg)</i>	<i>Mean of winks After 15" from instillation</i>	<i>Standard Error</i>
PG054/34	KSL + HCl	7.0	308	7.75	1.4
PG054/35	KSL	7.2	267	7.25	1.6
PG054/36	KSL + NaOH	8.0	289	1.71	0.4
PG054/37	KSL + NaOH	9.0	333	1.14	0.3
PG054/38	KSL + NaOH	9.5	403	4.13	1.1
PG054/53	KSL + NaOH	8.5	301	0.2	0.2
PG054/40	Artrosilene® fiale	7.3	308	9.25	1.9
PG054/41	NaCl	-	-	0.83	0.4

**Table 5 - Second session – First experiment**

<i>Batch</i>	<i>Composition</i>	<i>pH</i>	<i>Osmolality (mOsmol/kg)</i>	<i>Mean of winks After 15" from Instillation</i>	<i>Standard Error</i>
PG054/45	KSL + NaHCO <sub>3</sub>	7.0	359	5.1	1.0
PG054/46	KSL + NaHCO <sub>3</sub> + NaOH	7.5	351	3.0	0.8
PG054/47	KSL + NaHCO <sub>3</sub> + NaOH	8.0	358	1.5	0.3
PG054/48	KSL + NaHCO <sub>3</sub> + NaOH	8.5	382	2.1	0.8
PG054/49	KSL + NaHCO <sub>3</sub> + NaOH	9.0	395	3.1	0.7
PG054/50	KSL + NaHCO <sub>3</sub> + NaOH	9.5	455	6.1	1.4
PG054/51	Artrosilene® fiale	7.4	307	9.6	2.5
PG054/52	NaCl	-	-	1.2	0.6



**Table 6 - First session – Second experiment**

<i>Batch</i>	<i>Composition</i>	<i>pH</i>	<i>Osmolality (mOsmol/kg)</i>	<i>Mean of winks after 15" from instillation</i>	<i>Standard Error</i>
PG054/62	KSL + NaHCO <sub>3</sub> + HCl	7.0	356	5.9	0.8
PG054/63	KSL + HCl	7.0	276	6.8	1.0
PG054/64	KSL + NaHCO <sub>3</sub> + NaOH	8.0	362	2.0	0.4
PG054/65	KSL + NaOH	8.0	282	4.1	1.3
PG054/66	KSL + NaHCO <sub>3</sub> + NaOH	9.0	399	3.0	0.5
PG054/67	KSL + NaOH	9.0	336	1.9	0.6
PG054/68	Artrosilene <sup>®</sup> fiale	7.3	-	10.3	1.7
PG054/69	NaCl	-	-	0.4	0.2

**Table 7 - Second session – Second experiment**

<i>Batch</i>	<i>Composition</i>	<i>pH</i>	<i>Osmolality (mOsmol/kg)</i>	<i>Mean of winks after 15" from instillation</i>	<i>Standard Error</i>
PG054/70	KSL + NaOH	7.5	268	7.8	1.3
PG054/71	KSL + NaOH	8.5	301	1.9	0.5
PG054/72	KSL + NaOH	9.5	405	3.5	0.8
PG054/73	Artrosilene <sup>®</sup> fiale	7.3	282	8.8	1.7
PG054/74	NaCl	-	308	0.6	0.2
PG054/75	KSL + NaHCO <sub>3</sub> + NaOH	7.5	354	2.5	0.6
PG054/76	KSL + NaHCO <sub>3</sub> + NaOH	8.5	384	3.0	0.4
PG054/77	KSL + NaHCO <sub>3</sub> + NaOH	9.5	463	9.6	2.2

**Example 2**

## VAS evaluation

All clinical trials were performed by LCG (Bourn Hall Clinic, Cambridge, UK), except clinical trial KLS 0497 performed by Aster Clinical Research Center (Paris France), and clinical trial KLS 0101 performed by I.P.A.S. S.A.(Ligornetto, Switzerland).

Each treatment consisted in a deep intramuscular injection of one ampoule of test formulations in the upper outer quarter of the gluteus maximus. Each injection was performed within 10 minutes after preparation of the syringe and lasted 3-5 seconds. The intensity of pain at the injection site was evaluated by subjects and recorded on case report forms using the 100 mm Visual Analogue Scale.

Statistical elaboration was performed by STAT100 release 1.26 for Windows 95.

Data are imported in statistical software from Microsoft Excel by means of copy/paste function, printed and manually checked before starting the elaboration. All variables were described with N, mean, standard deviation, standard error of the mean.

't-test' was performed to compare the reference compound (Artrosilene®) against saline to verify the efficiency of the test.

ANOVA (One Way replicated measures) was performed to compare the pH-response profile of ketoprofen. Dunnett's test was applied.

Results are reported in Table 8, where VAS numbers are compared with rat winks numbers.

A correlation between the number of winks in rats and VAS (Visual Analogue Scale) number in humans has in fact been confirmed in our experiments.

Table 8 reports a summary of the results achieved with different formulations (relevant compositions are reported in Table 9): VAS number was taken immediately after injection, while rat winks were counted 15 seconds after instillation in rat's eye.

**Table 8**

<i>Formulation*</i>	<i>Clinic N°</i>	<i>N° of patients</i>	<i>Mean VAS value ± S.D.</i>	<i>N° of patients with VAS ≥ 50</i>	<i>N° of patients with VAS ≥ 75</i>	<i>Mean winks number</i>
KSL+Phosphate buffer pH 6.5	KSL0199	48	47.3±26.3	22 (45.83%)	7 (14.58%)	24.6
Artrosilene® fiale pH 7.0	KSL0196	18	46.9±25.6	9 (50%)	4 (22.22%)	9.49
Artrosilene® fiale pH 7.0	KSL0396	17	45.3±23.5	7 (41.18%)	3 (17.65%)	
Artrosilene® fiale pH 7.0	KSL0497	31	42.9±21.2	12 (38.71%)	3 (9.68%)	
Artrosilene® fiale pH 7.0	KSL0199	44	40.0±27.0	15 (34.09%)	6 (13.64%)	
KSL +NaHCO <sub>3</sub> pH 8.0	KSL0100	12	35.0±25.3	4 (33.33%)	1 (8.33%)	2.45

KSL +NaHCO <sub>3</sub> PH 8.5	KSL0101	32	20.4±16.2	2 (6.25%)	0	1.9
-----------------------------------	---------	----	-----------	-----------	---	-----

**Table 9 – Composition of formulations**

<i>KSL + phosphate buffer pH 6.5</i>	<i>Artrosilene® fiale pH 7.0</i>	<i>KSL +NaHCO<sub>3</sub> pH 8.0</i>	<i>KSL +NaHCO<sub>3</sub> pH 8.5</i>
KSL 160 mg	KSL 160 mg	KSL 160 mg	KSL 160 mg
NaH <sub>2</sub> PO <sub>4</sub> ·H <sub>2</sub> O 35.88 mg	Citric acid anhydrous 5 mg	NaHCO <sub>3</sub> 4 mg	NaHCO <sub>3</sub> 8 mg
NaOH q.s. to pH 6.5	NaOH q.s. to pH 7.0	NaOH q.s. to pH 8.0	NaOH q.s. to pH 8.5
Water for injection q.s. to 2mL	Water for injection q.s. to 2 mL	Water for injection q.s. to 2 mL	Water for injection q.s. to 2 mL

The correlation between VAS and number of winks in rats after administration of the same formulations is outlined in Figure 3.

Aqueous formulations of ketoprofen lysine salt (KSL) (80 mg/mL) and KSL formulations (80 mg/mL) containing sodium bicarbonate (4mg/mL) with pH in the range between 7.0 and 9.5 were tested. As a reference standard Artrosilene® fiale and a sodium chloride 0.9% solution were used. Results in the rat wink test showed that the number of winks was higher for the formulations with a pH value at the extreme limit of the investigated range.

The concave-shaped curve obtained from these experiments showed that formulations with intermediate pH value were better tolerated (i.e. the number of winks are closer to the value obtained with the saline isotonic solution).

An aqueous solution of KSL showed a minimum value at pH 8.5, with lower winking values in the range of pH between 8.0 and 9.5.

The aqueous solution of KSL + sodium bicarbonate showed the minimum winking effect at pH 8.0, with lower values in the pH range between 7.5 and 9.0.

The experiment was performed in duplicate, testing formulations with the same compositions, but of different batches, obtaining the same results in both experimental sets.

From an analysis of experimental data we have observed that the winks number caused by formulations with a pH in the range between 8.0 and 9.0 (KSL solutions and KSL + bicarbonate solutions) was comparably lower. In this pH range the effect on the reduction of the number of winks was significant. On the other side the osmolality didn't seem to have an effect on winks number.

In the second part of the study, the number of winks of KSL formulations was related to the VAS obtained testing in human the same formulations. A correlation with  $R=0.778$  was found and it was noticed that formulations with higher pH were also better tolerated in humans showing lower VAS values. In fact, focusing on the formulation at pH 8.5, it was found, as it is shown on the table 8, that its mean VAS value (20.4) is much lower than Artrosilene<sup>®</sup> fiale formulation (mean: 43.8). Moreover, 6.25% of the patients treated with pH 8.5 formulation showed a VAS value  $\leq 0$  and no patient showed a VAS number  $\geq 5$ , while 41% of patients to whom Artrosilene<sup>®</sup> fiale was injected showed a VAS value  $\leq 0$  and 15.8% showed a VAS  $\geq 5$ .

As shown in table 8, the VAS values of Artrosilene obtained from different clinical trials and performed in different clinical centres, are comparable.

This result was confirmed by winking test. In fact for Artrosilene<sup>®</sup> fiale a winking number of 9.49 was found, remarkably higher than 1.9 value found for the formulation at pH 8.5.

Considering the results obtained in the rat wink test and the correlation between VAS and winks number, we conclude that formulations with pH in the range between 8.0 and 9.0 are less painful. The preferred formulation which causes no pain upon injection is then an aqueous formulation having a pH of about 8.5.

## CLAIMS

1. A pharmaceutical composition suitable for parenteral administration having anti-inflammatory and analgesic property, characterized in that it contains an alkylammonium salt of a 2-arylpropionic acid selected from ketoprofen, ibuprofen, naproxen or tiaprofenic acid, in racemic or in enantiomeric form, in an aqueous solution at a pH in the range between 8 and 9, said solution being free of preservatives, co-solvents and supporting substances.
2. A pharmaceutical composition as claimed in claim 1, containing the L-lysine salt of ketoprofen.
3. A pharmaceutical composition as claimed in claim 2, containing sodium bicarbonate and sodium hydroxide at pH 8.5.

Figure 1






Figure 2



**Figure 3**

$$R = 0,778$$

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 03/11689

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K31/192

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

WPI Data, PAJ, EPO-Internal

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 6 342 530 B1 (DARKO LASZLO) 29 January 2002 (2002-01-29) column 4, line 62; claim 1 ---	1-3
A	US 5 895 789 A (GENTILE MARCO ET AL) 20 April 1999 (1999-04-20) claim 1 -----	1-3

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

### ° Special categories of cited documents:

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \* & \* document member of the same patent family

Date of the actual completion of the international search

21 January 2004

Date of mailing of the international search report

28/01/2004

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Beyss, E



# INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 03/11689

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 6342530	B1	29-01-2002	CA 2361160 A1 14-05-2002
			EP 1205181 A2 15-05-2002
			JP 2002193799 A 10-07-2002
US 5895789	A	20-04-1999	IT MI952777 A1 30-06-1997
			AT 232096 T 15-02-2003
			AU 1069897 A 28-07-1997
			BR 9607422 A 23-06-1998
			CZ 9702643 A3 12-11-1997
			DE 69626103 D1 13-03-2003
			DE 69626103 T2 04-12-2003
			DK 814797 T3 26-05-2003
			EA 599 B1 29-12-1999
			EP 0814797 A1 07-01-1998
			HK 1008777 A1 20-12-2002
			NO 973921 A 26-08-1997
			PL 322165 A1 19-01-1998
			SI 9620023 A 28-02-1998
			SK 113097 A3 04-02-1998
			CA 2213232 A1 10-07-1997
			CN 1176596 A ,B 18-03-1998
			ES 2192234 T3 01-10-2003
			HU 9801048 A2 28-10-1998
			WO 9724114 A1 10-07-1997
			PT 814797 T 30-06-2003
			TR 9700869 T1 21-12-1997